Reports of broader therapeutic potential for PN6047
PharmNovo AB announces today new preclinical findings supporting the potential of PN6047 in migraine and opioid withdrawal syndrome. The findings were generated through the company's NIDA-funded collaboration with researchers at Washington University School of Medicine.
The new data support the broader therapeutic potential of PharmNovo's lead candidate, PN6047, beyond neuropathic pain. In established preclinical models of migraine and headache disorders, PN6047 demonstrated efficacy while maintaining a favourable safety profile. The findings also support the potential of PN6047 in opioid withdrawal, where headache is a common and debilitating symptom.
Download the full press release below to learn more.
Reports of broader therapeutic potential for PN6047
PharmNovo AB announces today new preclinical findings supporting the potential of PN6047 in migraine and opioid withdrawal syndrome. The findings were generated through the company's NIDA-funded collaboration with researchers at Washington University School of Medicine.
The new data support the broader therapeutic potential of PharmNovo's lead candidate, PN6047, beyond neuropathic pain. In established preclinical models of migraine and headache disorders, PN6047 demonstrated efficacy while maintaining a favourable safety profile. The findings also support the potential of PN6047 in opioid withdrawal, where headache is a common and debilitating symptom.
Download the full press release below to learn more.
Latest news
View all
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
